Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.66 |
| ▸ | NAAA | Q02083 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11248504 | 0.98 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL2868723 | 0.98 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL9763677 | 0.98 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL11083072 | 0.98 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL2356495 | 0.98 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL25330125 | 0.98 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL5694314 | 0.98 | NAAA (0.68) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| Bromide SCHEMBL9028287 | 0.97 | NAAA (0.67) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL29708225 | 0.95 | HDAC3 (0.74) | HDAC3HDAC1HDAC2RAB9AEPHX2 | |
| SCHEMBL3241002 | 0.95 | HDAC3 (0.74) | HDAC3HDAC1HDAC2RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731934-B2 | HDAC inhibitor compounds and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS INC (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2017136943-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2017-08-17 | — | — | WO | disclosed |
| US-20170174619-A1 | HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9278103-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9168259-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-8552200-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2630123-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052167-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-04-26 | — | — | WO | disclosed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| EP-1763350-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006014168-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087338-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | HDAC3 2571/4885HDAC1 2609/4885HDAC2 3314/4885 |
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | KCNQ2, KCNQ1, KCNQ3 | HDAC3 209/4885HDAC1 624/4885HDAC2 411/4885 |
| US-20170174619-A1 | HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT | HDAC4, HDAC1, HDAC5 | HDAC3 4/4885HDAC1 2/4885HDAC2 5/4885 |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | TYMP, PNP, DUT | HDAC3 2571/4885HDAC1 2609/4885HDAC2 3314/4885 |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | HDAC3 209/4885HDAC1 624/4885HDAC2 411/4885 |
| US-11731934-B2 | HDAC inhibitor compounds and methods of treatment | HDAC4, HDAC1, HDAC5 | HDAC3 4/4885HDAC1 2/4885HDAC2 5/4885 |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | HDAC3 2571/4885HDAC1 2609/4885HDAC2 3314/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | HDAC3 1803/4885HDAC1 2556/4885HDAC2 2791/4885 |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | HDAC3 209/4885HDAC1 624/4885HDAC2 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.